---
schema_version: "secwatch.filing_event.v1"
accession: "0001999371-25-005877"
form_type: "8-K"
ticker: "TNXP"
cik: "0001430306"
company_name: "Tonix Pharmaceuticals Holding Corp."
filed_at: "2025-05-12T23:59:59+00:00"
generated_at: "2026-05-21T23:21:15.607532+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Tonix Q1 net loss $16.8M; cash $131.7M; PDUFA date Aug 15 for TNX-102 SL

## Summary
- Net loss $16.8M ($2.84/share) vs $14.9M ($535.72/share) in Q1 2024; product revenue $2.4M.
- Cash and equivalents $131.7M as of March 31, 2025; cash runway into Q2 2026.
- FDA PDUFA goal date Aug 15, 2025 for TNX-102 SL for fibromyalgia; if approved, first new drug in >15 years.
- Positive Phase 1 results for TNX-1500 anti-CD40L mAb; plans for Phase 2 in kidney transplant.
- Discontinued Phase 2 CATALYST study of TNX-1300 due to slow enrollment; not safety/efficacy.

## SEC filing metadata
- accession: 0001999371-25-005877
- form_type: 8-K
- ticker: TNXP
- cik: 0001430306
- company_name: Tonix Pharmaceuticals Holding Corp.
- filed_at: 2025-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1430306/000199937125005877/0001999371-25-005877-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1430306/000199937125005877/tnxp-8k_051225.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001999371-25-005877
- JSON: https://secwatch.observer/filing/0001999371-25-005877.json
- Plain text: https://secwatch.observer/filing/0001999371-25-005877.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.